Where Will C3.ai Stock Be in 1 Year?
C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…
Buy
53
QURE Quote, Financials, Valuation and Earnings
Last price:
$14.37
Seasonality move
:
-9.95%
Day range:
$14.37 - $15.00
52-week range:
$4.45 - $19.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.52x
P/B ratio:
23.40x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
61.62%
Market cap:
$788.4M
Revenue:
$27.1M
EPS (TTM):
-$4.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$5.9M | -$0.90 | -49.23% | -25.47% | $36.24 |
|
ARGX
argenx SE
|
$901.2M | $3.04 | 85.28% | 502.3% | $764.37 |
|
MRUS
Merus NV
|
$9.9M | -$1.15 | 41.37% | -39.39% | $90.20 |
|
PHAR
Pharming Group
|
$82.5M | -$0.01 | 11.82% | -25% | $30.33 |
|
PHVS
Pharvaris NV
|
-- | -$0.90 | -- | -46.46% | $33.86 |
|
PRQR
ProQR Therapeutics NV
|
$5M | -$0.17 | -26.75% | -63.67% | $8.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$14.40 | $36.24 | $788.4M | -- | $0.00 | 0% | 35.52x |
|
ARGX
argenx SE
|
$560.24 | $764.37 | $34.2B | 34.31x | $0.00 | 0% | 13.98x |
|
MRUS
Merus NV
|
$54.50 | $90.20 | $3.8B | -- | $0.00 | 0% | 66.65x |
|
PHAR
Pharming Group
|
$10.00 | $30.33 | $683.9M | -- | $0.00 | 0% | 2.52x |
|
PHVS
Pharvaris NV
|
$25.12 | $33.86 | $1.4B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$2.32 | $8.88 | $244.4M | -- | $0.00 | 0% | 10.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QURE
uniQure NV
|
60.5% | -5.009 | 8.9% | 11.33x |
|
ARGX
argenx SE
|
-- | -0.134 | -- | 6.40x |
|
MRUS
Merus NV
|
-- | 0.551 | -- | 5.34x |
|
PHAR
Pharming Group
|
29.23% | -0.909 | 15.42% | 2.00x |
|
PHVS
Pharvaris NV
|
-- | -0.824 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
5.57% | 1.651 | 3.6% | 4.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$1.4M | -$39.3M | -158.75% | -333.08% | -1788.9% | -$44.2M |
|
ARGX
argenx SE
|
$709.9M | $141.2M | 18.03% | 21.33% | 25.74% | -$147M |
|
MRUS
Merus NV
|
-- | -$75.7M | -45.56% | -45.56% | -285.94% | -$96.6M |
|
PHAR
Pharming Group
|
$70.8M | -$7.4M | -4.46% | -6.48% | -8.46% | -$56K |
|
PHVS
Pharvaris NV
|
-- | -$44.4M | -- | -- | -- | -$40.7M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$11.4M | -53.43% | -58.1% | -239.35% | -$16.9M |
uniQure NV vs. Competitors
-
Which has Higher Returns QURE or ARGX?
argenx SE has a net margin of -2784.75% compared to uniQure NV's net margin of 21.43%. uniQure NV's return on equity of -333.08% beat argenx SE's return on equity of 21.33%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV87.43% -$0.82 $85.3M ARGXargenx SE89.78% $2.58 $5.5B -
What do Analysts Say About QURE or ARGX?
uniQure NV has a consensus price target of $36.24, signalling upside risk potential of 151.68%. On the other hand argenx SE has an analysts' consensus of $764.37 which suggests that it could grow by 36.44%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 2 0 ARGXargenx SE16 1 0 -
Is QURE or ARGX More Risky?
uniQure NV has a beta of 0.077, which suggesting that the stock is 92.298% less volatile than S&P 500. In comparison argenx SE has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.097%.
-
Which is a Better Dividend Stock QURE or ARGX?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or ARGX?
uniQure NV quarterly revenues are $1.6M, which are smaller than argenx SE quarterly revenues of $790.7M. uniQure NV's net income of -$43.6M is lower than argenx SE's net income of $169.5M. Notably, uniQure NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 34.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 35.52x versus 13.98x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV35.52x -- $1.6M -$43.6M ARGXargenx SE13.98x 34.31x $790.7M $169.5M
-
Which has Higher Returns QURE or MRUS?
Merus NV has a net margin of -2784.75% compared to uniQure NV's net margin of -364.22%. uniQure NV's return on equity of -333.08% beat Merus NV's return on equity of -45.56%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV87.43% -$0.82 $85.3M MRUSMerus NV-- -$1.40 $596.1M -
What do Analysts Say About QURE or MRUS?
uniQure NV has a consensus price target of $36.24, signalling upside risk potential of 151.68%. On the other hand Merus NV has an analysts' consensus of $90.20 which suggests that it could grow by 65.51%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 2 0 MRUSMerus NV13 0 0 -
Is QURE or MRUS More Risky?
uniQure NV has a beta of 0.077, which suggesting that the stock is 92.298% less volatile than S&P 500. In comparison Merus NV has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.282%.
-
Which is a Better Dividend Stock QURE or MRUS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or MRUS?
uniQure NV quarterly revenues are $1.6M, which are smaller than Merus NV quarterly revenues of $26.5M. uniQure NV's net income of -$43.6M is higher than Merus NV's net income of -$96.5M. Notably, uniQure NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 35.52x versus 66.65x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV35.52x -- $1.6M -$43.6M MRUSMerus NV66.65x -- $26.5M -$96.5M
-
Which has Higher Returns QURE or PHAR?
Pharming Group has a net margin of -2784.75% compared to uniQure NV's net margin of -18.61%. uniQure NV's return on equity of -333.08% beat Pharming Group's return on equity of -6.48%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV87.43% -$0.82 $85.3M PHARPharming Group89.48% -$0.22 $303.7M -
What do Analysts Say About QURE or PHAR?
uniQure NV has a consensus price target of $36.24, signalling upside risk potential of 151.68%. On the other hand Pharming Group has an analysts' consensus of $30.33 which suggests that it could grow by 203.33%. Given that Pharming Group has higher upside potential than uniQure NV, analysts believe Pharming Group is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 2 0 PHARPharming Group2 0 0 -
Is QURE or PHAR More Risky?
uniQure NV has a beta of 0.077, which suggesting that the stock is 92.298% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHAR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHAR?
uniQure NV quarterly revenues are $1.6M, which are smaller than Pharming Group quarterly revenues of $79.1M. uniQure NV's net income of -$43.6M is lower than Pharming Group's net income of -$14.7M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 35.52x versus 2.52x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV35.52x -- $1.6M -$43.6M PHARPharming Group2.52x -- $79.1M -$14.7M
-
Which has Higher Returns QURE or PHVS?
Pharvaris NV has a net margin of -2784.75% compared to uniQure NV's net margin of --. uniQure NV's return on equity of -333.08% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV87.43% -$0.82 $85.3M PHVSPharvaris NV-- -$0.89 -- -
What do Analysts Say About QURE or PHVS?
uniQure NV has a consensus price target of $36.24, signalling upside risk potential of 151.68%. On the other hand Pharvaris NV has an analysts' consensus of $33.86 which suggests that it could grow by 34.8%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 2 0 PHVSPharvaris NV7 0 0 -
Is QURE or PHVS More Risky?
uniQure NV has a beta of 0.077, which suggesting that the stock is 92.298% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHVS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHVS?
uniQure NV quarterly revenues are $1.6M, which are larger than Pharvaris NV quarterly revenues of --. uniQure NV's net income of -$43.6M is higher than Pharvaris NV's net income of -$48.8M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 35.52x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV35.52x -- $1.6M -$43.6M PHVSPharvaris NV-- -- -- -$48.8M
-
Which has Higher Returns QURE or PRQR?
ProQR Therapeutics NV has a net margin of -2784.75% compared to uniQure NV's net margin of -223.04%. uniQure NV's return on equity of -333.08% beat ProQR Therapeutics NV's return on equity of -58.1%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV87.43% -$0.82 $85.3M PRQRProQR Therapeutics NV-- -$0.11 $90.5M -
What do Analysts Say About QURE or PRQR?
uniQure NV has a consensus price target of $36.24, signalling upside risk potential of 151.68%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 282.54%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV9 2 0 PRQRProQR Therapeutics NV6 0 0 -
Is QURE or PRQR More Risky?
uniQure NV has a beta of 0.077, which suggesting that the stock is 92.298% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.365, suggesting its less volatile than the S&P 500 by 63.535%.
-
Which is a Better Dividend Stock QURE or PRQR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PRQR?
uniQure NV quarterly revenues are $1.6M, which are smaller than ProQR Therapeutics NV quarterly revenues of $4.8M. uniQure NV's net income of -$43.6M is lower than ProQR Therapeutics NV's net income of -$10.6M. Notably, uniQure NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 35.52x versus 10.48x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV35.52x -- $1.6M -$43.6M PRQRProQR Therapeutics NV10.48x -- $4.8M -$10.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is the Ceiling for IONQ Stock?
IonQ (NYSE:IONQ) is a quantum computing startup that, like many…
Can FUBO Stock Double?
TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 12
MiNK Therapeutics [INKT] is up 727.94% over the past day.
Buy
51
NEGG alert for Jul 12
Newegg Commerce [NEGG] is up 74.03% over the past day.
Buy
68
ATRO alert for Jul 12
Astronics [ATRO] is up 16.28% over the past day.
